FindTrial
Sign In

Marizomib

DRUG6 trials

Sponsors

Celgene, European Organisation for Research and Treatment of Cancer - EORTC, National Cancer Institute (NCI), Dana-Farber Cancer Institute

Conditions

Anaplastic EpendymomaDiffuse GliomaDiffuse Intrinsic Pontine GliomaEpendymomaEpendymomasMultiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory

Phase 1

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
CompletedNCT02103335
CelgeneMultiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Start: 2014-06-05End: 2016-11-30Updated: 2017-11-22
Phase I Study of Marizomib + Panobinostat for Children With DIPG
TerminatedNCT04341311
Dana-Farber Cancer InstituteDiffuse Glioma, Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma +3
Start: 2020-08-10End: 2024-02-14Updated: 2024-02-15

Phase 2

Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma
TerminatedNCT03727841
National Cancer Institute (NCI)Anaplastic Ependymoma, Ependymoma, Ependymomas
Start: 2020-01-22End: 2021-04-30Updated: 2022-07-27
Marizomib Central Nervous System (CNS)
WithdrawnNCT05050305
Dana-Farber Cancer InstituteMultiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Start: 2024-03-31End: 2027-12-31Updated: 2024-07-16

Phase 3

A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
CompletedNCT03345095
European Organisation for Research and Treatment of Cancer - EORTCNewly Diagnosed Glioblastoma
Start: 2018-07-26End: 2023-06-30Updated: 2025-07-01

Unknown Phase

Expanded Access for Marizomib
NCT04644107
CelgeneSolid Tumor
Updated: 2020-11-25

Related Papers

Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the radiotherapy delineation benchmark case procedure.
2025-08-10
EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.
Journal of Clinical Oncology2021-05-2030 citations
P14.124 EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma
Neuro-Oncology2019-08-016 citations
Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma (GBM).
Journal of Clinical Oncology2019-05-2010 citations
EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.
Journal of Clinical Oncology2019-05-209 citations
ACTR-40. A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF MARIZOMIB (MRZ) WITH TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED WHO GRADE IV MALIGNANT GLIOMA (GLIOBLASTOMA, ndGBM): FULL ENROLLMENT RESULTS
Neuro-Oncology2018-11-011 citations
RBTT-08. EORTC 1709/CCTG CE.8: A PHASE III TRIAL OF MARIZOMIB IN COMBINATION WITH STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY VERSUS STANDARD TEMOZOLOMIDE-BASED RADIOCHEMOTHERAPY ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology2018-11-01